Bank of America’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bank of America’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-200	Closed	-$53.4K	–	8341
2024 Q1	$53.4K	Sell	200 -9,800	-98%	-$2.31M	﹤0.01%	6495
2023 Q4	$2.31M	Buy	+10,000	New	+$1.75M	﹤0.01%	4258
2023 Q3	–	Sell	-30,000	Closed	-$6.93M	–	7874
2023 Q2	$6.93M	Buy	+30,000	New	+$8.13M	﹤0.01%	3071
2019 Q1	–	Sell	-25,000	Closed	-$2.82M	–	7292
2018 Q4	$2.82M	Hold	25,000	–	–	﹤0.01%	3556
2018 Q3	$5.35M	Hold	25,000	–	–	﹤0.01%	3116
2018 Q2	$6.99M	Buy	+25,000	New	+$4.39M	﹤0.01%	2812
2013 Q3	–	Sell	-440	Closed	-$77K	–	7969
2013 Q2	$77K	Buy	+440	New	+$115K	﹤0.01%	6313

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America's MDGL Position: Q1 2026 in Review

Bank of America reduced its Madrigal Pharmaceuticals (MDGL) stake by 54% in Q1 2026, selling an estimated $108M and leaving 189,527 shares worth $99.2M. The position accounts for 0.01% of the portfolio, ranked #1120.

Bank of America first reported a position in MDGL in Q2 2013 and has held it in 51 quarters since. The position peaked at $242M in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

Bank of America held 189,527 shares of Madrigal Pharmaceuticals worth $99.2M as of Q1 2026.
Bank of America sold 226,498 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $108M.
Madrigal Pharmaceuticals made up 0.01% of Bank of America's portfolio in Q1 2026, its #1120 holding.
Bank of America first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
Bank of America's Madrigal Pharmaceuticals position peaked at $242M in Q4 2025.
378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.